MFG:ASXMagellan Financial Group Ltd Analysis
Data as of 2026-06-19 - not real-time
A$9.97
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Magellan Financial Group (MFG) is trading at A$9.97, comfortably above its 20‑day (8.97), 50‑day (9.18) and 200‑day (9.51) SMAs, indicating short‑term price strength, but the computed trend direction is still flagged as bearish, suggesting underlying weakness. The RSI sits at 71.8, placing the stock in overbought territory, while the MACD histogram is positive (0.156) and the signal line is bullish, creating a mixed technical picture. Fundamentally, revenue has slumped 31.6% YoY, yet the firm maintains robust gross (71.5%) and operating (51.1%) margins, with an ROE of 14% and a healthy cash position (A$115 m) versus minimal debt. Valuation metrics are contradictory: the PE of 12.3 is well below the industry average of 16.9, implying relative cheapness, but the DCF‑derived fair value of A$8.83 is below the current price, yielding a –6.5% downside and an “overvalued” signal. Volatility is elevated at 28% over the past 30 days, while beta is essentially neutral (‑0.008), indicating price swings are driven more by company‑specific factors than market moves. The recent ACCC approval of the merger with Barrenjoey Capital Partners sparked a 5.5% price jump, underscoring market optimism about potential synergies and a rebrand, but integration risk remains.
Given the absence of a dividend, a high‑margin, cash‑rich balance sheet, and a strategic merger that could broaden distribution channels, the stock may benefit from a longer‑term value play. However, the steep revenue decline, overbought technical signals, and modest upside relative to fair value suggest caution in the near term. Investors should monitor post‑merger execution, revenue recovery, and any shifts in market sentiment before committing larger positions.
Given the absence of a dividend, a high‑margin, cash‑rich balance sheet, and a strategic merger that could broaden distribution channels, the stock may benefit from a longer‑term value play. However, the steep revenue decline, overbought technical signals, and modest upside relative to fair value suggest caution in the near term. Investors should monitor post‑merger execution, revenue recovery, and any shifts in market sentiment before committing larger positions.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Overbought RSI and mixed MACD signals
- Recent merger approval driving short‑term price rally
- Limited upside vs DCF fair value
Medium Term
1–3 yearsNeutral
Model confidence: 7/10
Key Factors
- Potential synergies and expanded distribution from Barrenjoey merger
- Strong profit margins offsetting revenue decline
- Valuation near industry PE average but still above DCF estimate
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- High operating cash flow and low debt supporting financial stability
- Strategic rebrand and broader market reach post‑merger
- Undervalued relative to peers on a PE basis and attractive ROE
Key Metrics & Analysis
Financial Health
Revenue Growth-31.60%
Profit Margin53.28%
P/E Ratio12.3
ROE14.07%
ROA8.45%
Debt/Equity0.38
P/B Ratio1.8
Op. Cash FlowA$144.8M
Free Cash FlowA$116.2M
Industry P/E16.9
Technical Analysis
TrendBearish
RSI71.8
SupportA$8.32
ResistanceA$10.00
MA 20A$8.97
MA 50A$9.18
MA 200A$9.51
MACDBullish
VolumeIncreasing
Fear & Greed Index92.14
Valuation
Fair ValueA$8.83
Target PriceA$9.32
Upside/Downside-6.50%
GradeFair
TypeBlend
Risk Assessment
Beta-0.01
Volatility28.33%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.